Breaking News Instant updates and real-time market news.

NTEC

Intec Pharma

$0.56

-2.4277 (-81.19%)

, NVS

Novartis

$94.25

0.67 (0.72%)

13:14
07/22/19
07/22
13:14
07/22/19
13:14

Oppenheimer downgrades Intec Pharma after 'major setback' of trial miss

As previously reported, Oppenheimer analyst Jay Olson downgraded Intec Pharma (NTEC) to Perform from Outperform after the company announced "a major setback" as the ACCORDANCE study did not achieve statistical superiority to Sinemet on the primary endpoint of reduction in daily OFF time. He noted that the company still has additional opportunities with other drugs, including proprietary partnerships with Novartis (NVS) and Merck (MRK), but said the read across from AP-CD/LD to other AP applications in different diseases is uncertain following this morning's news.

NTEC

Intec Pharma

$0.56

-2.4277 (-81.19%)

NVS

Novartis

$94.25

0.67 (0.72%)

MRK

Merck

$81.41

0.02 (0.02%)

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

  • 09

    Sep

  • 16

    Sep

  • 20

    Sep

  • 25

    Sep

  • 02

    Oct

NTEC Intec Pharma
$0.56

-2.4277 (-81.19%)

10/05/18
ROTH
10/05/18
INITIATION
Target $8.5
ROTH
Buy
Intec Pharma resumed with a Buy at Roth Capital
Roth Capital analyst Scott Henry resumed coverage of Intec Pharma with a Buy rating and $8.50 price target, citing a favorable risk/reward for Accordion Pill - Carbidopa/Levodopa, or AP-CD/LD, the company's Phase 3 Parkinson's treatment. Key catalysts for shares include PK data in 4Q18 and pivotal data in mid-2019, the analyst tells investors in a research note.
07/22/19
MAXM
07/22/19
DOWNGRADE
MAXM
Hold
Intec Pharma downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Intec Pharma to Hold from Buy after the company's "Accordion" pill failed in a Phase 3 trial. Intec shares have declined about 84% to 48c per share in late morning trading.
07/22/19
OPCO
07/22/19
DOWNGRADE
OPCO
Perform
Intec Pharma downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Jay Olson downgraded Intec Pharma to Perform from Outperform after the company announced that the ACCORDANCE study did not achieve statistical superiority to Sinemet on the primary endpoint of reduction in daily OFF time.
NVS Novartis
$94.25

0.67 (0.72%)

06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/18/19
WELS
07/18/19
NO CHANGE
WELS
Novartis' Sandoz trends a negative for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris said that while Novartis' (NVS) Sandoz Q2 results were better than expected, they were mainly driven by ex-U.S. performance, and the analyst believes this could have "negative implications for other companies with significant U.S. commodity generics, such as Teva (TEVA) and Mylan (MYL) though perhaps moreso for Mylan." Maris noted that on the conference call, Novartis stated, "If you take out one-time, certain one-time effects, you would see that in the U.S. the base business continues to have declines in the mid-teens consistent with what we've seen in past quarters, so we haven't seen yet a stabilization in the core GX business in the U.S." The analyst concluded that the commentary is consistent with his "continued caution on generics."
MRK Merck
$81.41

0.02 (0.02%)

07/03/19
MZHO
07/03/19
INITIATION
Target $97
MZHO
Buy
Mizuho starts Merck with Buy rating, $97 price target
Mizuho analyst Mara Goldstein last night initiated coverage of Merck with a Buy rating and $97 price target. The company is larger than Keytruda, but the "drug is too big to ignore," Goldstein tells investors in a research note. She believes Merck can overcome the loss of exclusivity on its Januvia franchise given Keytruda's "dominance" in immuno-oncology. The latter will drive operating margin expansion over the next five years, contends Goldstein.
07/03/19
07/03/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Gol Linhas (GOL) upgraded to Buy from Neutral at Goldman Sachs with analyst Bruno Amorim saying the suspension of Avianca Brasil's operations on May 24 should provide a "significant boost" to unit revenues in the Brazilian domestic market in upcoming quarters. 2. Cinemark (CNK) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould saying the "tough" comp facing the company in Q2 is now priced into the shares. 3. Latam Airlines (LTM) downgraded to Sell from Neutral at Goldman Sachs with analyst Bruno Amorim saying "fierce" competition in the Spanish speaking countries and "still weak" pricing in the international markets will likely offset the positive effect from Avianca Brasil's bankruptcy. 4. Inogen (INGN) downgraded to Underweight from Neutral at JPMorgan with analyst Robert Marcus, who continues to view Inogen as a "potentially attractive story" longer-term, saying he believes the company's near-term outlook is weighed down by uncertainty and market headwinds. 5. Merck (MRK) initiated with a Buy rating and a $97 price target at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AKAM

Akamai

$90.95

-0.13 (-0.14%)

21:13
09/18/19
09/18
21:13
09/18/19
21:13
Downgrade
Akamai rating change  »

Akamai downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

DB

Deutsche Bank

$8.06

-0.125 (-1.53%)

20:32
09/18/19
09/18
20:32
09/18/19
20:32
Hot Stocks
Deutsche Bank lowers prime lending rate to 5.00% from 5.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRVB

Provention Bio

$9.70

0.33 (3.52%)

20:31
09/18/19
09/18
20:31
09/18/19
20:31
Syndicate
Provention Bio 5M share Spot Secondary priced at $8.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 19

    Sep

DRI

Darden

$127.40

1.31 (1.04%)

20:25
09/18/19
09/18
20:25
09/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

XGN

Exagen

$0.00

(0.00%)

19:48
09/18/19
09/18
19:48
09/18/19
19:48
Syndicate
Exagen 3.6M share IPO priced at $14.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

PING

Ping Identity

$0.00

(0.00%)

19:35
09/18/19
09/18
19:35
09/18/19
19:35
Syndicate
Ping Identity 12.5M share IPO priced at $15.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CBS

CBS

$43.38

0.08 (0.18%)

, T

AT&T

$36.77

-0.39 (-1.05%)

19:04
09/18/19
09/18
19:04
09/18/19
19:04
Periodicals
Viacom, CBS, WarnerMedia pull e-cigarette ads from networks, CNBC says »

CBS (CBS),…

CBS

CBS

$43.38

0.08 (0.18%)

T

AT&T

$36.77

-0.39 (-1.05%)

VIA

Viacom

$27.94

-0.06 (-0.21%)

VIAB

Viacom

$25.77

0.02 (0.08%)

BTI

British American Tobacco

$36.90

0.06 (0.16%)

MO

Altria Group

$40.84

-0.47 (-1.14%)

PM

Philip Morris

$71.58

-0.4 (-0.56%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

CRON

Cronos Group

$10.96

-0.205 (-1.84%)

18:57
09/18/19
09/18
18:57
09/18/19
18:57
Hot Stocks
Cronos Group CEO: We focus on supply and the consumer »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

, SVRA

Savara

$2.49

-0.14 (-5.32%)

18:46
09/18/19
09/18
18:46
09/18/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

SVRA

Savara

$2.49

-0.14 (-5.32%)

CBPO

China Biologic

$103.19

0.37 (0.36%)

NCR

NCR Corp.

$33.62

0.77 (2.34%)

MSFT

Microsoft

$138.53

1.13 (0.82%)

TNDM

TNDM

X

U.S. Steel

$12.45

-0.51 (-3.94%)

PRVB

Provention Bio

$9.70

0.33 (3.52%)

PAA

Plains All American

$21.87

-0.315 (-1.42%)

COST

Costco

$292.47

0.96 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 23

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 21

    Oct

  • 22

    Oct

  • 27

    Oct

  • 05

    Nov

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

TECD

Tech Data

$103.32

-0.59 (-0.57%)

18:41
09/18/19
09/18
18:41
09/18/19
18:41
Hot Stocks
Tech Data CEO: We are confident in our company and where we are going »

Tech Data CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

18:34
09/18/19
09/18
18:34
09/18/19
18:34
Periodicals
AT&T, Dish not in discussions over DirecTV deal, Reuters reports »

AT&T (T) and Dish…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

AGCO

Agco

$76.04

-0.16 (-0.21%)

18:30
09/18/19
09/18
18:30
09/18/19
18:30
Hot Stocks
Agco CEO: We are on schedule in the U.S. »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.63

-0.31 (-2.08%)

18:22
09/18/19
09/18
18:22
09/18/19
18:22
Periodicals
Petrobras raises gasoline, diesel prices in wake of Saudi attacks, Reuters says »

Petrobras has boosted the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$123.69

-0.28 (-0.23%)

18:01
09/18/19
09/18
18:01
09/18/19
18:01
Hot Stocks
Celanese increases Vinyl Acetate Monomer price in EMEA by EUR50/MT »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STI

SunTrust

$68.57

0.48 (0.70%)

18:00
09/18/19
09/18
18:00
09/18/19
18:00
Hot Stocks
SunTrust lowers prime lending rate to 5% from 5.25% »

Following the Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBS

Webster Financial

$48.84

0.43 (0.89%)

17:53
09/18/19
09/18
17:53
09/18/19
17:53
Hot Stocks
Webster Financial lowers prime lending rate to 5.0% from 5.25% 

Effective September 19.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 13

    Nov

HSBC

HSBC

$38.19

-0.1 (-0.26%)

17:52
09/18/19
09/18
17:52
09/18/19
17:52
Hot Stocks
HSBC decreases prime lending rate to 5% from 5.25% »

HSBC Bank USA and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

HES

Hess Corp.

$66.91

-0.92 (-1.36%)

17:50
09/18/19
09/18
17:50
09/18/19
17:50
Hot Stocks
Hess Corp. COO sells 17,750 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

CSCO

Cisco

$49.32

-0.1 (-0.20%)

, DDOG

Datadog

$0.00

(0.00%)

17:46
09/18/19
09/18
17:46
09/18/19
17:46
Periodicals
Cisco approached Datadog with $7B+ takeover bid, Bloomberg says »

Cisco (CSCO) approached…

CSCO

Cisco

$49.32

-0.1 (-0.20%)

DDOG

Datadog

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 13

    Nov

  • 19

    Sep

ASB

Associated Banc-Corp

$20.23

0.075 (0.37%)

17:46
09/18/19
09/18
17:46
09/18/19
17:46
Hot Stocks
Associated Banc-Corp lowers prime rate to 5.0% from 5.25% 

Effective September 19.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$140.69

-0.93 (-0.66%)

17:45
09/18/19
09/18
17:45
09/18/19
17:45
Hot Stocks
SPDR Gold Shares holdings rise to 883.60MT from 880.37MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

17:44
09/18/19
09/18
17:44
09/18/19
17:44
Periodicals
AT&T exploring options to part with DirecTV unit, WSJ says »

AT&T (T) is looking…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

CBPO

China Biologic

$103.19

0.37 (0.36%)

17:43
09/18/19
09/18
17:43
09/18/19
17:43
Hot Stocks
China Biologic up 7% after receiving 'going private' proposal for $120 per share »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

17:42
09/18/19
09/18
17:42
09/18/19
17:42
Hot Stocks
AT&T, Dish move higher after WSJ report that AT&T has explored DirecTV options »

Shares of both AT&T…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

GSK

GlaxoSmithKline

$41.06

-0.04 (-0.10%)

17:41
09/18/19
09/18
17:41
09/18/19
17:41
Periodicals
FDA panel recommends approval of GSK's nicotine oral spray, Reuters says »

An independent expert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.